Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease with no cure. For patients, access to coordinated and comprehensive care is essential to improving quality of life and extending survival. Research shows that Multidisciplinary clinics increase life expectancy for ALS patients by up to 40%, while also reducing long-term healthcare costs. Florida is home to seven certified ALS multidisciplinary centers. These centers work in collaboration with the ALS Association of Florida to deliver coordinated care, reduce burdens on families, and advance research. Despite their proven effectiveness, these clinics faced challenges in maintaining sustainable funding. Without reliable state support, patients risked losing access to comprehensive care, leaving many to rely on fragmented community-based services. This would not only decrease patient outcomes but also increase costs to Medicaid and hospitals across Florida.
The Mayernick Group led lobbying efforts to secure state funding. Through targeted advocacy and relationship-building, The Mayernick Group successfully secured funding to ensure continued access to multidisciplinary ALS care in Florida.
The Mayernick Group’s advocacy ensured that Florida ALS patients have continued access to world-class care that not only improves survival but also strengthens the state’s healthcare and research landscape. By combing patient-centered storytelling with data-driven policy arguments, the firm demonstrated how strategic lobbying can achieve meaningful outcomes for this vulnerable population.